

Impact of Cold Agglutinin Disease and its related Fatigue on Patients' Daily Life: an Online Survey among 50 US Patients

Florence Joly^{1*}, Lisa Anne Schmitt², Patricia Ann McGee Watson³, Emilie Pain⁴, Damien Testa^{4#}

¹Sanofi, Chilly-Mazarin, France ²Sanofi Genzyme, Cambridge, MA, USA ³Cold Agglutinin Disease Foundation (CADF), Cherry Hill, NJ, USA ⁴Carenity, Paris, France [#]Current Affilitaiton: Moona, Paris, France *Corresponding/Presenting author: Florence Joly

INTRODUCTION

Cold Agglutinin Disease (CAD), primary or secondary, is a rare disease and type of **autoimmune hemolytic anemia** characterized by autoantibodies that bind to red blood cells (RBC) at below core body temperature [1, 2]. In addition to cold-induced symptoms, the anemia and hemolysis observed in CAD causes **numerous symptoms** including fatigue, RBC agglutination, dizziness, shortness of breath, headaches; however, these symptoms are reported in very **few publications** [2]. Disease severity may fluctuate. There is no approved drug for the treatment of CAD [3].

OBJECTIVE

The present study aims to assess the **impact of CAD** and its related effects on patients' daily life.

RESPONDENTS' PROFILE (n=50)

METHODS

An Internet-based survey hosted on **Carenity**, an online patient community, was conducted among patients registered on the **CAD Unraveled website** (https://www.cadunraveled.com/) and members from the **Cold Agglutinin Disease Foundation**.

Study Characteristics

- Inclusion criteria: Adult patients living with CAD in the USA
- Sample size: 50 respondents
- Number of questions: 39 closed questions and 5 openended questions
- Data collection period: September 2020
- Framework of the study: Voluntary, opportunity to withdraw at any time and no financial incentive



RESULTS

A. CAD SYMPTOMS EXPERIENCED BY PATIENTS

88% of patients experienced at least one symptom prior to diagnosis. The symptoms most often reported included fatigue (fatigue / tiredness / lack of stamina / weakness) (74%), shortness of breath (38%), and acrocyanosis (36%).

88% of patients have already experienced an **episode of increased intensity/sensitivity of their CAD symptoms** and **72%** have had an **episode of new CAD symptoms**. On average, patients have experienced between **4 and 5** episodes in the past 12 months. **Fatigue** is the main symptom (**89%**) experienced by patients during these episodes. **Shortness of breath** (**66%**), **dark urine** (**47%**), and **headaches** (**43%**) were also often reported.

Focus on Fatigue

Fatigue was experienced on a **daily basis** by **44%** of patients, **27%** experienced it **several times a week** and **16%** only **after exertion**.




Fig. 3: Evolution of the Level of Fatigue throughout the Day (n=45)

B. IMPACT OF CAD ON PATIENTS' DAILY LIFE


More than half of the patients considered

Focus on impact on professional life

Focus on impact on household finances



Personal life and physical well-being are the impacted aspects. Patients also most spontaneously reported impact on their emotional well-being (22/50). Patients are more affected during episodes of increased **intensity/sensitivity** (median≥ 8/10, with 10=very strong impact) they or when experience usual/regular symptoms (i.e. symptoms experienced on a daily basis) (median≥ 6/10).



C. MANAGEMENT METHODS USED TO MANAGE THE CAD






Fig. 6: Management methods used at the time of the survey (n=50)




Fig. 7: Satisfaction regarding management methods used at the time of the survey (n=46)

Focus on Fatigue

Almost all patients who experienced fatigue had also implemented a solution to cope with it: taking breaks during the day (71%), managing supply of energy (60%) or taking vitamins (58%). On average, patients implemented 5 solutions.

Only **28%** of patients are **satisfied** with the solutions they have implemented to cope with fatigue.

CONCLUSION

CAD is a challenging and **life-impacting condition**. Fatigue has a significant impact on the different aspects of patients' daily lives. Personal life and physical well-being are some of the most impacted aspects of patients' lives. This survey shows that there is a need for a better management of this disease.

Funding: This study was funded by Sanofi-Genzyme.

Acknowledgements: The authors wish to thank all the CAD patients who participated in this survey and Cori Forster for her contributions to the design of the online survey.

